Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0016884,
umls-concept:C0017636,
umls-concept:C0021102,
umls-concept:C0025664,
umls-concept:C0030705,
umls-concept:C0178932,
umls-concept:C0205355,
umls-concept:C0205374,
umls-concept:C0231175,
umls-concept:C0302350,
umls-concept:C0442711,
umls-concept:C0596545,
umls-concept:C0596790,
umls-concept:C0851346,
umls-concept:C1513822,
umls-concept:C1518321,
umls-concept:C1521828,
umls-concept:C1522673,
umls-concept:C1527148,
umls-concept:C1627358,
umls-concept:C1880171,
umls-concept:C2349975
|
| pubmed:issue |
2
|
| pubmed:dateCreated |
1996-10-24
|
| pubmed:abstractText |
Three interstitial implant trial groups (one permanent low-dose rate 125I and two temporary high-dose rate 125I implants) in glioblastoma patients ('newly diagnosed' and 'failed') were compared to non-randomized similar control groups for efficacy. The results formed the basis for the BTCG 87-01 national implant trial. The 'pilot' trial demonstrated: 1) the effectiveness of a temporary high-dose rate 125I implant in 'failed' and 'newly diagnosed' patients; 2) the ability of a multicenter consortium to adhere to a standard protocol; 3) a methodology to insure quality assurance; and 4) the possibility of the future adjuvant application of hyperthermia using a single catheter system.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0167-594X
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
26
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
141-55
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:8787856-Brain Neoplasms,
pubmed-meshheading:8787856-Glioblastoma,
pubmed-meshheading:8787856-Humans,
pubmed-meshheading:8787856-Infusion Pumps, Implantable,
pubmed-meshheading:8787856-Iodine Radioisotopes,
pubmed-meshheading:8787856-Middle Aged,
pubmed-meshheading:8787856-Quality Assurance, Health Care,
pubmed-meshheading:8787856-Radiotherapy, Adjuvant,
pubmed-meshheading:8787856-Recurrence,
pubmed-meshheading:8787856-Research Design,
pubmed-meshheading:8787856-Survival Rate
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
On the development of an interstitial radiation protocol for a multicenter consortium. Experience with permanent low-dose rate and temporary high-dose rate 125I implants in 'failed' and 'newly diagnosed' glioblastoma patients: quality assurance methodology and a possible future adjuvant for therapeutic enhancement.
|
| pubmed:affiliation |
Center for Neuro-Oncology, Western Pennsylvania Hospital, Pittsburgh, USA.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|